Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 8 studies | 33% ± 15% | |
glutamatergic neuron | 3 studies | 45% ± 22% | |
astrocyte | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 29% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 3069.64 | 653 / 653 | 98% | 21.12 | 590 / 605 |
brain | 99% | 2541.40 | 2620 / 2642 | 95% | 32.97 | 673 / 705 |
skin | 97% | 788.91 | 1763 / 1809 | 83% | 9.00 | 390 / 472 |
ovary | 99% | 1180.18 | 179 / 180 | 79% | 6.06 | 338 / 430 |
kidney | 100% | 1104.40 | 89 / 89 | 72% | 9.40 | 650 / 901 |
uterus | 99% | 1354.19 | 169 / 170 | 46% | 3.69 | 212 / 459 |
prostate | 100% | 1358.27 | 244 / 245 | 42% | 1.35 | 209 / 502 |
breast | 97% | 729.67 | 446 / 459 | 42% | 2.12 | 473 / 1118 |
bladder | 100% | 1085.71 | 21 / 21 | 14% | 0.65 | 71 / 504 |
esophagus | 77% | 915.09 | 1108 / 1445 | 34% | 1.35 | 62 / 183 |
stomach | 85% | 549.29 | 305 / 359 | 16% | 0.75 | 45 / 286 |
eye | 0% | 0 | 0 / 0 | 100% | 16.54 | 80 / 80 |
blood vessel | 99% | 902.91 | 1322 / 1335 | 0% | 0 | 0 / 0 |
adipose | 96% | 766.12 | 1151 / 1204 | 0% | 0 | 0 / 0 |
intestine | 84% | 790.84 | 814 / 966 | 6% | 0.24 | 32 / 527 |
lung | 60% | 241.04 | 348 / 578 | 25% | 1.06 | 285 / 1155 |
heart | 83% | 431.11 | 714 / 861 | 0% | 0 | 0 / 0 |
spleen | 71% | 282.72 | 171 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 21% | 72.48 | 55 / 258 | 32% | 3.08 | 74 / 230 |
pancreas | 33% | 108.20 | 107 / 328 | 15% | 0.49 | 26 / 178 |
tonsil | 0% | 0 | 0 / 0 | 42% | 1.76 | 19 / 45 |
liver | 10% | 33.54 | 23 / 226 | 24% | 1.14 | 99 / 406 |
muscle | 4% | 14.38 | 33 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0006915 | Biological process | apoptotic process |
GO_0072659 | Biological process | protein localization to plasma membrane |
GO_1901379 | Biological process | regulation of potassium ion transmembrane transport |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0071805 | Biological process | potassium ion transmembrane transport |
GO_0008076 | Cellular component | voltage-gated potassium channel complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005886 | Cellular component | plasma membrane |
GO_0005634 | Cellular component | nucleus |
GO_0005267 | Molecular function | potassium channel activity |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0015459 | Molecular function | potassium channel regulator activity |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
Gene name | KCNIP3 |
Protein name | Calsenilin (A-type potassium channel modulatory protein 3) (DRE-antagonist modulator) (DREAM) (Kv channel-interacting protein 3) (KChIP3) Potassium voltage-gated channel interacting protein 3 |
Synonyms | CSEN KCHIP3 DREAM |
Description | FUNCTION: Calcium-dependent transcriptional repressor that binds to the DRE element of genes including PDYN and FOS. Affinity for DNA is reduced upon binding to calcium and enhanced by binding to magnesium. Seems to be involved in nociception (By similarity). .; FUNCTION: Regulatory subunit of Kv4/D (Shal)-type voltage-gated rapidly inactivating A-type potassium channels, such as KCND2/Kv4.2 and KCND3/Kv4.3. Modulates channel expression at the cell membrane, gating characteristics, inactivation kinetics and rate of recovery from inactivation in a calcium-dependent and isoform-specific manner. .; FUNCTION: May play a role in the regulation of PSEN2 proteolytic processing and apoptosis. Together with PSEN2 involved in modulation of amyloid-beta formation. . |
Accessions | Q9Y2W7 ENST00000698060.1 ENST00000295225.10 [Q9Y2W7-1] ENST00000468529.1 [Q9Y2W7-3] A0A8V8TMV8 |